500,000 option-exercise shares are part of an officer's planned sale at Pacific Biosciences (PACB).
Pacific Biosciences officer Jim Gibson plans to sell 661,815 common shares, valued at approximately $1.9 million, on October 6, 2026. The sale includes 500,000 shares from stock-option exercise and 161,815 shares from restricted stock units. This transaction is reported via a Form 144 SEC filing, with Morgan Stanley Smith Barney LLC acting as the broker.
PACB Stock Slides As UBS Starts Coverage With Neutral Call
Pacific Biosciences of California Inc. (PACB) stock slid by nearly 5% after UBS initiated coverage with a Neutral rating and a $1.35 price target, despite the stock recently trading much higher. UBS included PACB in its coverage of 25 life science and diagnostics tools companies, classifying the sector as a long-term "GDP plus" growth market. While the new coverage brings institutional attention, PACB remains a high-volatility trading vehicle due to its cash-burning financials, making it a battleground between its long-term industry story and current financial realities.
PacBio Deepens AI Drug-Discovery Push With TychoBio Deal — PACB Stock Takes A Breather After 103% Rally
PacBio announced a partnership with TychoBio to deepen its involvement in AI-based drug discovery, which will involve generating full-length RNA data from over 10,000 samples for TychoBio's AI models. Despite this new venture and other AI projects with Basecamp Research and Google, PacBio's stock experienced a tumble after a significant rally, and the company recently cut its full-year 2026 revenue forecast. The stock's performance and financial outlook present a mixed picture for investors.
PacBio and TychoBio Collaborate to Train AI Models for Rare Disease RNA Therapeutics
PacBio and TychoBio announced a collaboration to generate full-length RNA data using PacBio's HiFi sequencing and Kinnex long-read RNA sequencing. TychoBio will use this data from over 10,000 samples to train AI models for designing RNA therapies, particularly for rare diseases. This partnership aims to enhance the understanding of RNA regulation and accelerate the development of safer and more efficient therapeutic designs.
Pacific Biosciences stock hits a new 52-week high
Pacific Biosciences (PACB) stock reached a new 52-week high on October 5, 2026, trading at EUR 2.56, an increase of 14.29% from its previous close. This surge occurred despite the company reporting second-quarter 2026 revenues of USD 39.00 million, missing analyst expectations, and reducing its full-year revenue guidance. The stock's performance is attributed to after-hours trading, showcasing a mixed operating backdrop with declining instrument revenue but increased consumables revenue.
Why PacBio (PACB) Stock Is Trading Up Today
Shares of Pacific Biosciences of California (PACB) surged by 9.9% following an announcement that EpiSign Inc. and Geneyx Genomex Ltd. partnered to integrate genomic and epigenomic analysis for rare disease interpretation, incorporating PacBio HiFi sequencing data. This collaboration extends automated episignature analysis for over 300 disorders to Geneyx customers. Despite cooling off by day's end, the stock closed up 15% and has seen significant volatility, reaching a new 52-week high after a previous 29.7% gain related to EpiSign's METRIC 5-base launch.
PACB5630687 Bond Profile: Coupon and Redemption
This article provides a detailed profile of the PACB5630687 bond issued by Pacific Biosciences of California, Inc. It outlines key facts such as the issuer type, issue and maturity dates, face value, and minimum denomination. The profile also covers the bond's interest payment details, including a 1.38% fixed semi-annual coupon, and redemption information, noting an outstanding amount of $441.00 million USD.
Pacific Biosciences of California (PACB) Rises Higher Than Market: Key Facts
Pacific Biosciences of California (PACB) stock closed up 1.2% at $2.54, outperforming the S&P 500's daily gain. The company's shares have increased by 93.08% over the last month, significantly surpassing its sector and the broader market. Despite this, the company holds a Zacks Rank of #4 (Sell), with upcoming earnings projected to show a decrease in EPS and revenue compared to the previous year.
PACB Stock Climbs As Traders Eye Conference Catalyst
Pacific Biosciences of California Inc. (PACB) stock has climbed by 5.7% due to anticipation surrounding its appearance at the Morgan Stanley 24th Annual Global Healthcare Conference. Despite significant losses and negative margins, PACB maintains a strong cash position. The company's recent stock performance shows a sharp short-term uptrend, attracting momentum traders who are closely watching for any new catalysts from the conference.
Pacific Biosciences: Stock Surges As New Use Case Seen - But Caution Is Warranted (PACB)
Pacific Biosciences' stock surged following the launch of EpiSign METRIC 5-base, which integrates its HiFi sequencing into a broader clinical epigenomics platform. Despite a significant total addressable market and advanced technology, the company's revenue growth remains stagnant, and it continues to incur heavy losses. The article issues a Hold rating due to PACB's lack of profitability and slow adoption compared to larger competitors, advising caution despite the recent positive product news.
Pacific Biosciences Up Over 30%, On Pace for Largest Percent Increase Since July 2024 -- Data Talk
Pacific Biosciences (PACB) stock surged over 30% today, marking its largest percentage increase since July 2024. The significant rise in stock value indicates strong market reaction or positive company news contributing to this notable performance.
Why Is PacBio (PACB) Stock Soaring Today
Shares of Pacific Biosciences of California (PACB) surged by 29.7% following EpiSign's launch of EpiSign METRIC 5-base, a software enabling DNA methylation analysis on PacBio's HiFi sequencing platform. This new platform, which also supports Illumina and Oxford Nanopore systems, broadens episignature analysis capabilities. The stock's significant jump reflects its high volatility and the market's positive reaction to this development, despite previous volatility and a decline in value over the past five years for long-term investors.
PACB Stock Grinds Higher As Traders Eye Morgan Stanley Chat
Pacific Biosciences of California Inc. (PACB) stock has risen by 6.43% due to optimism surrounding strong genomics demand and an upcoming fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference. Traders are closely monitoring the event for insights into management's strategy, cash utilization, and future outlook, as the company, despite improving revenue, is still operating at a significant loss. The stock's recent price action shows steady accumulation, making the conference a key catalyst for short-term trading opportunities.
Asset turnover of Pacific Biosciences of California, Inc. – HAN:P09
This article focuses on the asset turnover of Pacific Biosciences of California, Inc. (P09) traded on the Hannover Stock Exchange. It provides a financial overview of the company, highlighting its trading status and related market data. The content is presented within the TradingView platform context.
PACB Stock Grinds Higher As Traders Eye Morgan Stanley Chat
Pacific Biosciences of California Inc. (PACB) stock is rising ahead of its management's participation in the Morgan Stanley 24th Annual Global Healthcare Conference. Despite significant revenue growth, the company remains unprofitable with negative margins and substantial long-term debt. Traders are closely watching the upcoming fireside chat for insights into the company's strategy, cost controls, and cash runway, as recent price action shows a steady accumulation.
Why PacBio (PACB) Stock Is Trading Up Today
Shares of genomics company Pacific Biosciences of California (PACB) rose after Sampled, a genomics provider, announced a five-year contract worth up to $27.1 million from the U.S. Department of Veterans Affairs. This agreement involves using PacBio Revio sequencing systems to support research for the Million Veteran Program. Despite the positive news, PacBio's shares have been highly volatile, and the stock is down 6.8% year-to-date.
Pacific Biosciences of California, Inc. (PACB) Stock Price, News, Quote & History
This page provides a comprehensive overview of Pacific Biosciences of California, Inc. (PACB), including its current stock price, historical data, financial performance, and analyst insights. The company, which designs and manufactures sequencing solutions, shows a current stock price of 1.5750 USD with a market cap of 489.558M. The content details the company's products, target markets, employee count, and its performance against the S&P 500 benchmark.
How to build the scientific case that gets your grant funded
This article focuses on how to build a strong scientific case for grant applications, emphasizing the importance of compelling evidence and data. It details how to identify impactful benchmarks and relevant scientific literature to support technology choices, especially for sequencing grants. The piece also highlights the necessity of a robust feasibility section, ensuring all technical and infrastructural aspects align with the proposed budget and research goals.
PACB Stock Firms Up Ahead Of Morgan Stanley Healthcare Chat
Pacific Biosciences of California Inc. (PACB) stock has seen a 7.72% increase due to positive sentiment surrounding its genomic sequencing advancements, ahead of its leadership's participation in the Morgan Stanley 24th Annual Global Healthcare Conference. This event provides PACB with a platform to discuss its long-read sequencing strategy and profitability roadmap, potentially serving as a short-term trading catalyst depending on management's commentary regarding guidance, cash runway, and demand trends. Despite current financial challenges including negative operating income and net losses, the company holds significant cash reserves, making the conference crucial for addressing market concerns about its growth trajectory and path to profitability.
CCORF Maintains Pacific Biosciences of California(PACB.US) With Buy Rating
CCORF has reiterated its Buy rating for Pacific Biosciences of California (PACB.US). The article does not provide further details on the rationale behind this rating or any financial analysis.
PacBio to Participate in the Morgan Stanley 24?? Annual Global Healthcare Conference
PacBio announced its management will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026, at 4:50 PM ET. A live webcast of the event will be available on the company's investor page, with a replay accessible for 30 days afterward. The company, a developer of high-quality sequencing solutions, is based in Menlo Park.
PACB Cuts 2026 Outlook as Clinical Adoption Faces Its Crucial Test
Pacific Biosciences (PACB) has lowered its 2026 revenue outlook due to weaker instrument demand and slower adoption of its SPRQ-Nx system, despite improving clinical activity. The company now expects cash-flow breakeven in 2028, later than initially projected, raising the stakes for execution on consumables utilization and margins. PACB faces challenges including manufacturing transition costs, elevated expenses, and competitive market pressures, leading to a cautious near-term outlook with a Zacks Rank #4 (Sell).
PacBio to Participate in the Morgan Stanley 24ᵗʰ Annual Global Healthcare Conference
PacBio (NASDAQ: PACB) announced its management will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026, at 4:50 PM ET in New York. A live webcast of the event will be available on the company's investors page, with a replay accessible for at least 30 days afterwards. PacBio is a life science technology company specializing in high-quality sequencing solutions for various research applications.
HiFi sequencing sets the benchmark for environmental health metabarcoding
A new benchmarking study demonstrates that PacBio HiFi sequencing offers the most reliable results for environmental metabarcoding, outperforming Illumina and Oxford Nanopore platforms. HiFi sequencing provides lower error rates, recovers more taxa, and captures full-length genetic barcodes, which is crucial for accurate biodiversity assessment and ecological inference. This makes it an ideal tool for environmental research, conservation, and ecosystem monitoring, especially with advancements like SPRQ-Nx chemistry improving throughput and cost-effectiveness.
PACB Cuts 2026 Outlook as Clinical Adoption Faces Its Crucial Test
Pacific Biosciences of California (PACB) has reduced its 2026 revenue outlook due to weaker instrument demand and a slower-than-anticipated transition to its SPRQ-Nx system. Despite improvements in clinical activity and consumables growth, the company faces challenges with gross margin recovery and has pushed its cash-flow breakeven target to 2028. This revision highlights the critical need for successful execution in consumables utilization and margin improvement to validate clinical adoption as a sustainable growth driver.
Whole Genome And Exome Sequencing Market Analysis Highlights Growth To $7.63 Billion By 2030 At 24.8% CAGR
The whole genome and exome sequencing market is projected to reach $7.63 billion by 2030, growing at a CAGR of 24.8%. This growth is fueled by technological advancements, increasing adoption in personalized medicine and diagnostics, and significant investments in sequencing infrastructure. Key players are focusing on ultra-fast NGS analysis to enhance speed and affordability, further driving market expansion.
Single Molecule Real Time Sequencing Market Research Reveals Strong 8.4% CAGR Outlook Through 2030
The single molecule real time sequencing market is projected to reach $5.15 billion by 2030, growing at an 8.4% CAGR due to increased demand for genome analysis and adoption of long-read sequencing. Key trends include the rise of long-read technologies and AI-based genomic analytics, with major players like Pacific Biosciences and Oxford Nanopore Technologies driving innovation. The market is segmented by workflow, product, application, and end-user, highlighting diverse growth opportunities.
PACB Stock Pops As New CEO Backs Powerful Vega Upgrade
Pacific Biosciences of California Inc. (PACB) stock surged by over 13% due to optimism surrounding its sequencing platform. The company announced a new CEO, Mark Van Oene, and a significant upgrade to its Vega benchtop sequencer, boosting data output and reducing costs. Despite ongoing financial losses, PACB's strong balance sheet and technological advancements are attracting active traders looking for momentum plays.
Chromosome level genome assembly and full-length transcriptome of blacktip trevally ( Caranx heberi )
This study presents the first high-quality chromosome-level genome assembly and full-length transcriptome of the blacktip trevally (Caranx heberi), a potential brackishwater aquaculture species. Researchers used PacBio HiFi reads, Illumina short reads, and Hi-C data to generate a 618.71 Mb genome with 24 chromosome-level scaffolds, along with transcriptomic data from seven tissues. These comprehensive genomic resources will aid in the domestication, aquaculture development, and further research into the species' nutritional potential, ecological adaptations, and evolutionary biology.
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Given Average Recommendation of "Reduce" by Analysts
Analysts have given Pacific Biosciences of California, Inc. (NASDAQ:PACB) an average "Reduce" recommendation, with an average 12-month price target of $1.83, significantly higher than its opening price of $1.23. The company recently missed quarterly earnings expectations, reporting a loss of $0.14 per share against an estimated $0.13, and revenue of $39.01 million compared to $42.90 million expected. Despite the stock trading near its 12-month low, several institutional investors have increased their holdings.
Pacific Biosciences CEO Mark van Oene sells $30,409 in stock
Pacific Biosciences CEO Mark van Oene sold 26,911 shares of the company's common stock for a total of $30,409. This transaction was to cover tax withholding obligations associated with restricted stock units. Following the sale, Van Oene directly holds over 2.7 million shares, while the company's stock trades near its 52-week low.
Pacific Biosciences CEO Mark van Oene sells $30,409 in stock
Pacific Biosciences CEO Mark van Oene sold 26,911 shares of company stock for $30,409 on August 17, 2026. This transaction was primarily to cover tax withholding obligations associated with the vesting of restricted stock units. The sale occurred as PACB stock trades near its 52-week low, and the company recently reported a revenue miss and adjusted its full-year outlook.
Insider Selling: Pacific Biosciences of California (NASDAQ:PACB) Insider Sells 26,911 Shares of Stock
Pacific Biosciences of California (NASDAQ:PACB) insider Oene Mark Van sold 26,911 shares of the company's stock for approximately $30,409. The sale was primarily to cover tax withholding obligations related to vested equity awards, reducing his holdings by 0.98%. This transaction occurred as PACB shares traded near their 12-month low after reporting quarterly results that missed analyst expectations, leading to a "Reduce" consensus rating from analysts.
PacBio (NASDAQ: PACB) CEO share sale covers RSU tax withholding
PacBio (NASDAQ: PACB) CEO Mark Van Oene sold 26,911 shares of common stock on August 17, 2026, at a weighted average price between $1.13 and $1.15 per share. This sale was automatically conducted to cover tax withholding obligations associated with the vesting of restricted stock units, rather than being a discretionary market sale. Following the transaction, Van Oene directly holds 2,705,853 shares of PACB common stock.
PacBio Cuts Outlook as SPRQ-Nx Transition Slows, Targets 2028 Cash-Flow Positivity
Pacific Biosciences of California (PacBio) has lowered its revenue outlook due to a slower-than-expected customer transition to its lower-priced SPRQ-Nx chemistry and weakening demand for Vega systems from academic and government sectors. The company is implementing a restructuring to cut costs, aiming for $15 million to $20 million in annual compensation savings and an additional $30 million to $40 million reduction in spending by 2027. PacBio is targeting cash-flow positivity by 2028, contingent on launching a new ultra-high-throughput platform, improving compute economics, and achieving gross margins near 50%.
PacBio Cuts Outlook as SPRQ-Nx Transition Slows, Targets 2028 Cash-Flow Positivity
PacBio has revised its revenue outlook downward due to a slower-than-anticipated customer transition to its lower-priced SPRQ-Nx chemistry and weakened demand for Vega systems from academic and government sectors. The company is implementing cost-reduction measures, including a workforce reduction, targeting significant annual savings and a further spending reduction in 2027. PacBio aims for cash-flow positivity by 2028, contingent on the launch of a new ultra-high-throughput platform, improved compute economics, and successful customer conversion to SPRQ-Nx.
ARK reports 9.59% stake in Pacific Biosciences (PACB)
ARK Investment Management LLC and Catherine D. Wood have reported a beneficial ownership of 9.59% in Pacific Biosciences of California, Inc. (PACB), amounting to 29,781,416 shares. This disclosure, made via a SCHEDULE 13G/A filing, details their sole and shared voting and dispositive powers over these shares. The filing indicates a neutral sentiment and moderate impact on the stock.
PACIFIC BIOSCIENCES (PACB) CEO granted 1.97M options and 489K RSUs
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) CEO Mark Van Oene was granted 1.97 million stock options and 489,130 Restricted Stock Units (RSUs) on August 10, 2026. The stock options have an exercise price of $1.15 per share and vest over 36 monthly installments, while the RSUs vest in equal annual installments over three years. Following these grants, Van Oene directly holds 2,732,764 common shares of PACB.
Earnings Release: Here's Why Analysts Cut Their Pacific Biosciences of California, Inc. (NASDAQ:PACB) Price Target To US$2.29
Analysts have cut their price target for Pacific Biosciences of California (NASDAQ:PACB) to US$2.29 after the company reported a moderately negative quarterly result, with revenue falling short of estimates and statutory losses meeting expectations. The lowered price target reflects concerns about increased forecasted losses and slower revenue growth compared to the wider industry. Analysts now expect per-share losses to increase to US$0.44 in 2026, while revenue growth is predicted to slow significantly.
Pacific Biosciences of California, Inc. $PACB Shares Sold by Renaissance Technologies LLC
Renaissance Technologies LLC significantly reduced its stake in Pacific Biosciences of California (NASDAQ:PACB) by 35.4% in the first quarter, selling 1,361,500 shares. This comes as analyst sentiment for PACB is generally bearish, with an average "Reduce" rating and an average price target of $1.83. The company also reported a quarterly loss and revenue that missed analyst estimates.
Earnings Release: Here's Why Analysts Cut Their Pacific Biosciences of California, Inc. (NASDAQ:PACB) Price Target To US$2.29
Analysts have cut their price target for Pacific Biosciences of California (NASDAQ:PACB) to US$2.29 after the company reported quarterly results showing a 15% drop in investment. Revenues fell short of estimates, and while statutory losses were in line, analysts now expect increased losses for 2026 and slower revenue growth compared to the wider industry. The consensus price target has fallen, reflecting concerns about the company's future valuation and performance.
Earnings Release: Here's Why Analysts Cut Their Pacific Biosciences of California, Inc. (NASDAQ:PACB) Price Target To US$2.29
Analysts have lowered their price target for Pacific Biosciences of California (NASDAQ:PACB) to US$2.29 after the company's recent earnings report, which saw revenue fall short of estimates and increased projected losses per share for 2026. The revised forecasts indicate a slowdown in revenue growth compared to historical performance and expectations for the broader industry, prompting a more negative outlook from analysts.
Pacific Biosciences of California (NASDAQ:PACB) Cut to "Sell" at Wall Street Zen
Wall Street Zen has downgraded Pacific Biosciences of California (NASDAQ:PACB) from a "hold" to a "sell" rating. The company recently missed its quarterly earnings and revenue estimates, reporting a loss of $0.14 per share and $39.01 million in revenue. Analysts currently hold a "Reduce" consensus rating for PACB, with a target price of $1.83, and major institutional investors have adjusted their holdings in the company.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 2026: Revenue $39.01M, EPS ($0.14) — 10-Q Summary
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) reported its current quarter 2026 results, showing largely flat revenue year-over-year at $39.01M and a net loss that widened to ($44.74M), though diluted EPS remained ($0.14). The company is focusing on shifting towards clinical and commercial accounts, increasing Revio adoption, and implementing operational efficiencies expected to reduce operating expenses by $30–$40M annually by the end of 2027. Key milestones include the SPRQ‑Nx launch, the sale of short‑read technology assets, and a licensing agreement with PGI.
Pacific Biosciences of California, Inc. Stock 12‑Month Price Target Cut to $2.29, Implies 76% Upside
The average 12-month price target for Pacific Biosciences of California, Inc. (PACB) stock has been lowered from $2.46 to $2.29 by 6 analysts, suggesting a potential upside of approximately 76% from its August 5th closing price. Despite the target cut, the consensus rating from 7 covering analysts remains a "Buy," with 4 Buys, 2 Holds, and 1 Sell recommendation.
Pacific Biosciences of California Q2 Earnings Call Highlights
Pacific Biosciences of California (NASDAQ: PACB) reported Q2 2026 revenue of $39 million, remaining flat year-over-year, alongside a leadership change and a reduced full-year revenue forecast. The company is facing challenges with the slower-than-expected rollout of its new SMRT Next sequencing chemistry and funding constraints in academic and government sectors. Despite these headwinds, PacBio is focusing on scaling its clinical-market approach and expects consumables growth to accelerate later in 2026 as customers adopt the new chemistry.
PacBio Announces Second Quarter 2026 Financial Results
PacBio reported its second-quarter 2026 financial results, with total revenue of $39.0 million, driven by growth in consumables and new Revio and Vega placements. The company also announced the global commercial rollout of its SPRQ-Nx chemistry, offering whole genome sequencing at a list price of $345 USD. Despite a GAAP net loss of $44.7 million, PacBio projects full-year 2026 revenue to be between $155 million and $165 million.
TD Cowen Maintains Pacific Biosciences of California(PACB.US) With Buy Rating, Maintains Target Price $3
TD Cowen has reiterated its Buy rating on Pacific Biosciences of California (PACB.US) and maintained its target price at $3. This indicates a continued positive outlook from the firm regarding the company's stock performance.
PacBio Q2 Earnings Meet Estimates, Revenues Miss, 2026 Sales View Cut
PacBio reported an adjusted loss per share of 14 cents for Q2 2026, meeting estimates, but revenues of $39 million missed expectations and were down 2% year over year. The company reduced its 2026 revenue guidance to $155-$165 million due to weaker instrument sales, funding constraints in the Americas and Asia-Pacific, and slower-than-expected adoption of new chemistry. Despite challenges, PacBio highlighted growth in consumables revenue, strong clinical demand, and increased revenues in EMEA.
Pacific Biosciences of California Q2 Earnings Call Highlights
Pacific Biosciences of California (PACB) reported Q2 2026 revenue of $39 million, largely flat year-over-year, and announced a leadership change with Mark Van Oene succeeding Christian Henry as CEO. The company lowered its full-year revenue outlook due to slower rollout of new sequencing chemistry and funding constraints in academic markets. Despite these challenges, PacBio saw growth in consumables revenue and highlighted the global rollout of its SMRT Next chemistry and the increasing adoption of long-read sequencing in clinical diagnostics.
